| INTRODUCTION
Crohn's disease (CD) is a chronic inflammatory and destructive bowel disease characterised by phases of relapse and remission. It is essential to obtain long-term deep remission to prevent irreversible gastrointestinal damage and disability. [1] [2] [3] The use of anti-tumor necrosis factor (TNF) agents have dramatically changed the prognosis of patients with moderate-to-severe CD with better long-term outcomes. 4 However, two-thirds of patients develop a loss of response or intolerance to anti-TNF and other treatments are required. [5] [6] [7] [8] Ustekinumab, a human monoclonal antibody that targets the p40 subunit of interleukin (IL)-12
and IL-23 and inhibits T-helper 1 and T-helper 17 pathways involved in CD, was shown to be effective in inducing and maintaining a clinical response in a phase III placebo-controlled trial in CD patients. 9 Moreover, ustekinumab has recently been licensed in CD.
Several retrospective cohort studies have reported that ustekinumab induces a short and intermediate-term clinical response in patients with CD refractory to anti-TNF therapy. [10] [11] [12] [13] Our group reported data in 122 patients with severe refractory CD included in a multicentre retrospective cohort who began subcutaneous (SC) ustekinumab. 11 A clinical response was observed in 65% of patients at 3 months with a sustained response in about two-thirds of them during the first year of treatment.
However, long-term data on ustekinumab in CD are lacking.
The aim of the present study was to evaluate the long-term efficacy and safety of ustekinumab and identify predictive factors of ustekinumab failure-free persistence in patients included in this cohort of anti-TNF refractory CD patients.
| MATERIALS AND METHODS

| Selection of patients
We performed a retrospective, observational cohort study in 19 French and one Swiss tertiary centres affiliated with the Groupe d'Etude
Th erapeutique des Affections Inflammatoires du tube Digestif (GETAID).
We previously published results in an initial cohort of 122 consecutive patients who began SC ustekinumab for active CD from March 2011 to December 2014 in the participating centres with a median follow-up of 9.8 months. 11 We included patients from this population in the present study if they met the following criteria: (1) clinical response (defined as a significant improvement of CD-related clinical symptoms assessed by the patient's physician leading to continued ustekinumab treatment) at 3 months (primary responders) or during the first year of treatment (late responders), and (2) follow-up until November 2016.
The protocol was approved by ethics committee (Comit e Consultatif sur le Traitement de l'Information en mati ere de Recherche dans le domaine de la Sant e N°15.177).
| Data collection
The inclusion date corresponded to the first SC administration of ustekinumab. rate, the Harvey Bradshaw Index (HBI) and clinical assessment, the presence of concomitant immunosuppressant or steroids, and endoscopic evaluation were also recorded at baseline and at the end of follow-up.
| Primary and secondary outcomes
The primary objective was ustekinumab failure-free persistence in initial responders to ustekinumab 12, 24 and 36 months after inclusion. Ustekinumab failure was defined as: (1) Safety data were recorded retrospectively from the medical records for each patient. We reported adverse events leading to ustekinumab discontinuation and severe adverse events (SAE) requiring hospitalisation and/or led to disability or death.
| Statistical analysis
Descriptive data were presented as frequencies (number) or medians (interquartile range (IQR)). The Kaplan-Meier method was used to assess cumulative ustekinumab failure-free persistence 12, 24, 36 months after treatment was begun and at the end of follow-up.
Univariate and multivariable analysis were performed to identify independent predictive factors of ustekinumab failure-free persistence described by the odds ratio (OR) and 95% confidence interval (95% CI). P < 0.05 was considered to be significant. | 589
December 2014 were eligible for the study. Seventy-nine of these patients achieved a clinical response at 3 months (primary responders) and were included in the present follow-up study. Nine of the 43 patients who did not respond to ustekinumab 3 months after inclusion achieved a clinical response during the first year of treatment (late responders) and were also included. Finally, 88 patients responded to ustekinumab during the first year and were included in the present study ( Figure 1 ).
The demographic and clinical characteristics of the 88 included patients at inclusion are summarised in Table 1 The results of univariate and multivariable analysis to identify independent factors of ustekinumab failure-free persistence at 24 months are shown in Table 2 . Female gender and concomitant immunosuppressants at inclusion were associated, but nonsignificantly, with ustekinumab failure-free persistence in univariate analysis (OR = 0.33, 95% CI: 0.10-1.05; P = 0.05 and OR 5.5, 95% CI:
1.21-24.8; P = 0.07, respectively). There were no predictive factors associated with ustekinumab efficacy on univariate and multivariable analysis.
| Outcome of ustekinumab in the entire population
The duration of follow-up in the present cohort was a median 26.6
(13.4-34.4) months and 3 (3%) patients were lost to follow-up.
Forty-seven of the 85 remaining patients maintained ustekinumab and 38 stopped this treatment. Figure 3 summarises for pregnancy. Twenty-seven of the 32 (31%) patients with ustekinumab failure had loss of response and 5 (6%) developed intolerance.
Among the 27 patients with loss of response to ustekinumab, 12 (14%) patients underwent surgery during the follow-up: 11 patients with surgical resection and one perianal drainage. Taking into account withdrawal of ustekinumab for all reasons, including failure and also pregnancy and remission, the cumulative probability of ustekinumab maintenance in the 88 patients was 80% at 12 months, 67% at 24 months and 59% at 36 months ( Figure S1 ). We specified outcome of patients who stopped ustekinumab in Table S2 .
Thirty-two patients required a dose intensification of ustekinumab during follow-up. That was effective in 18 (56%) including a dose increase in two patients, interval reduction in seven, and both in nine. An IS was introduced in two patients who continued maintenance with ustekinumab.
Among the 88 patients included, 10 various regimens were identified at last news (summarised in Table S1 ). The most common regimen was 90 mg every 8 weeks in 45 patients (51%).
| Efficacy of ustekinumab on perianal lesions
Nine of the 88 included patients received ustekinumab for perianal disease with a clinical remission during follow-up in six. Three patients who were in clinical remission, respectively, after 12, 25
and 30 months of follow-up, stopped ustekinumab: one patient for personal reasons (move to Australia), one for pregnancy and one patient for a severe adverse event (development of an anal adenocarcinoma). Three patients stopped ustekinumab because of loss of response at 6, 24 and 26 months, respectively.
| Safety of ustekinumab
At the end of follow-up, five patients stopped ustekinumab because of side effects including pulmonary infection (n = 1), a flare of hidradenitis suppurativa (n = 1), acne (n = 1), disabling myalgia (n = 1) and anal adenocarcinoma (n = 1).
One severe adverse event was reported in a patient who developed an anal adenocarcinoma. The anal adenocarcinoma developed in a 32-year-old man with 26-year paediatric onset Crohn's disease. | 591
This patient was treated with ustekinumab for 30 months. Radiochemotherapy was begun after ileostomy with no recurrence at 6 months. Adverse events are listed in Table 3 .
No injection site reactions, opportunistic infections or deaths were reported.
| DISCUSSION
This study reports the real-life experience of the long-term followup of anti-TNF refractory CD patients receiving ustekinumab treatment, in a multicentre and large cohort, with a median time under ustekinumab treatment of more than 2 years. Two-thirds of these 88 CD patients who were refractory to most current available biological treatments maintained ustekinumab without loss of response, intolerance or surgery at 2 years. There was a clinical improvement in all patients who maintained ustekinumab and high rates of biological and endoscopic responses (74% and 82%, respectively); of note, the CRP rate was available in 91% of the patients and an endoscopic evaluation was available in 60% of them. Importantly more than one-third of the patients required ustekinumab optimisation during follow-up and responded to intensification. In a recent study, authors reported that ustekinumab through levels above 4.5 lg/mL was associated with biomarker reduction and endoscopic response median follow-up of only 7.9 months. 10 We showed that ustekinumab was highly effective in CD patients refractory to anti-TNF (65% at 3 months) in the GETAID cohort with a median follow-up of 9.8 months. 11 Two other retrospective studies also assessed the effi- should be noted that in this phase III trial, only 60% of the patients receiving ustekinumab had previously received anti-TNF therapy.
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Our study reports the longest follow-up period with ustekinumab in CD patients with a median treatment duration of 26.6 months.
Moreover, all patients had failed treatment with one anti-TNF agent, and more than 90% had received two anti-TNF agents. Treatment options in highly refractory CD are limited and surgery is often the only option, with an increased risk of short bowel syndrome and disability. After 2 years of follow-up in highly refractory CD patients, we observed a clinical response to ustekinumab in more than twothird of patients without surgery. There are several limitations to the present study, mainly due to its retrospective design and the absence of the usual clinical and endoscopic scores. However, it is important to note that the data were prospectively collected from referral centres in the GETAID group. Moreover, we used ustekinumab failure-free persistence as primary objective, that may be considered as a surrogate outcome.
However, long-term treatment maintenance without any major event meets the real-life expectations of gastroenterologists and CD patients, who aim to avoid intestinal damage and progressive disability to improve quality of life. 18 Furthermore, we reported objective response to ustekinumab treatment with 39% of the patient with a mucosal healing and 82% with an endoscopic improvement. In a population of anti-TNF refractory CD patients, mucosal healing and also endoscopic improvement are relevant targets. We failed to identify predictors of long-term efficacy of ustekinumab. However, a trend for an association of ustekinumab failure-free persistence and concomitant immunosuppressants at inclusion was identified on univariate analysis but not on multivariable analysis probably because of the size of the cohort. Finally, ustekinumab trough levels and the rate of antibodies against ustekinumab were not available. However, recent data reported that monitoring of ustekinumab drug concentrations were not associated with clinical outcome but were only associated with biomarker reduction and endoscopic response to ustekinumab with a through concentration above 4.5 lg/mL. 14, 22 Along this, monitoring ustekinumab concentration is not currently recommended in practice.
In conclusion, while waiting for the long-term extension phase of IMUNITI, we have reported the long-term efficacy of ustekinumab in patients with refractory CD. More than half of these patients had maintained ustekinumab treatment after more than two years. These | 593 results suggest that ustekinumab should be considered to be an interesting, extended and safe therapeutic option in CD patients who are refractory to anti-TNF treatment.
